ArticleFrontiers in pharmacology2021

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide.

Yi-Ting Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.